Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 3/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zamifenacin SCHEMBL1933745 | 1.00 | ADRA1D (0.46) | ADRA1DADRA1AADRA1BKDM4EMEN1 | |
| Zamifenacin SCHEMBL4603503 | 0.99 | ADRA1D (0.46) | ADRA1DADRA1AADRA1BKDM4EMEN1 | |
| Zamifenacin SCHEMBL8938193 | 0.93 | KDM4E (0.45) | ADRA1DADRA1AADRA1BKDM4EMEN1 | |
| Zamifenacin SCHEMBL3227612 | 0.93 | KDM4E (0.45) | ADRA1DADRA1AADRA1BKDM4EMEN1 | |
| Zamifenacin SCHEMBL13957310 | 0.92 | SLC6A2 (0.41) | ADRA1DADRA1AADRA1BMAPK1MCHR1 | |
| Zamifenacin SCHEMBL13957195 | 0.92 | SLC6A2 (0.41) | ADRA1DADRA1AADRA1BMAPK1MCHR1 | |
| Zamifenacin SCHEMBL13957205 | 0.91 | NOS2 (0.42) | ADRA1DADRA1AADRA1BMEN1MAPK1 | |
| SCHEMBL8938462 | 0.90 | KCNH2 (0.44) | ADRA1DADRA1AADRA1BKDM4ENOS2 | |
| Zamifenacin SCHEMBL13957196 | 0.90 | ADRA1D (0.45) | ADRA1DADRA1AADRA1BKDM4EMEN1 | |
| Zamifenacin SCHEMBL13957218 | 0.90 | NOS2 (0.41) | ADRA1DADRA1AADRA1BKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 560 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4581166-A1 | CHRM3 AS A MARKER AND TARGET FOR COLON CANCER THERAPY | Indivumed GmbH (DE) | 2025-07-09 | — | — | EP | claimed |
| US-20250073237-A1 | METHODS OF TREATING OR PREVENTING PRETERM LABOR | VISCO ANTHONY G (US) | 2025-03-06 | — | — | US | claimed |
| WO-2024047001-A1 | CHRM3 AS A MARKER AND TARGET FOR COLON CANCER THERAPY | INDIVUMED GMBH (DE) | 2024-03-07 | — | — | WO | claimed |
| US-20240066018-A1 | CHRM3 AS A MARKER AND TARGET FOR CANCER THERAPY | INDIVUMED GMBH (DE) | 2024-02-29 | — | — | US | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| US-20220160711-A1 | METHODS OF TREATING OR PREVENTING PRETERM LABOR | VISCO ANTHONY G (US) | 2022-05-26 | — | — | US | claimed |
| US-11285141-B2 | Composition and methods for the treatment of myopia | Seinda Pharmaceutical Guangzhou Corporation (CN) | 2022-03-29 | — | — | US | claimed |
| WO-2022023496-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-02-03 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060241134-A1 | Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility | ALTANA PHARMA GA (DE) | 2006-10-26 | — | — | US | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| EP-1644043-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA Pharma AG (DE) | 2006-04-12 | — | — | EP | claimed |
| US-20050107349-A1 | Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | US | claimed |
| WO-2004105795-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA PHARMA AG (DE) | 2004-12-09 | — | — | WO | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| EP-0350309-B1 | PIPERIDINE DERIVATIVES | Pfizer Limited (GB) | 1992-11-11 | — | — | EP | claimed |
| US-5089505-A | Anticholinergic agents | PFIZER INC. (US) | 1992-02-18 | — | — | US | claimed |
| EP-0350309-A1 | Piperidine derivatives | Pfizer Limited (GB) | 1990-01-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107349-A1 | Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith | CHRM3, CYSLTR2, CHRM2 | ADRA1D 190/4885ADRA1A 224/4885ADRA1B 160/4885 |
| US-20220160711-A1 | METHODS OF TREATING OR PREVENTING PRETERM LABOR | CHRM3, ADRB3, CHRNA3 | ADRA1D 59/4885ADRA1A 42/4885ADRA1B 49/4885 |
| US-20250073237-A1 | METHODS OF TREATING OR PREVENTING PRETERM LABOR | CHRM3, ADRB3, CHRNA3 | ADRA1D 59/4885ADRA1A 42/4885ADRA1B 49/4885 |
| US-11285141-B2 | Composition and methods for the treatment of myopia | CHRM3, CHRM2, MYOC | ADRA1D 99/4885ADRA1A 74/4885ADRA1B 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.